Randomized, placebo-controlled Phase 2a study of SPL026 met its primary endpoint demonstrating a clinically significant reduction in depressive ...
The reduction in depression and anxiety symptoms 3 months after completing ten AMHSP sessions indicates a slow but meaningful benefit of the programme and supports the potential of a low-intensity, ...
The Rapid RCT Lab has worked with 16 departments across NYU Langone and completed 47 trials, and we are currently involved in ...
A phase 4 randomized controlled trial has found that shortened preventive tuberculosis (TB) regimens—one or three months of isoniazid plus rifapentine (1HP or 3HP)—are safe and effective ...
A digital pathology AI model to predict immune-oncology biomarker status and pembrolizumab response in a real-world cohort of patients with colorectal and breast cancer. Changes in non-small cell lung ...
‘A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial’ by David Erritzoe et al. was published in Nature Medicine at 16:00 UK time on ...
Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial Patients with advanced lung cancer reporting at least moderate ...
The Rapid RCT Lab is a nationally-leading team conducting innovative, rapid RCTs to improve the delivery of services at the ...
John Flanagan, PhD, presented new research at WVC 2026 that shows that a purpose-formulated, low-digestible carbohydrate diet combined with structured caloric restriction substantially increases short ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results